Premium
PARICALCITOL IN SECONDARY HYPERPARATHYROIDISM AND THE SURVIVAL BENEFIT IN PATIENTS WITH CHRONIC KIDNEY DISEASE
Author(s) -
AlBaaj Fouad,
Yadav Punit,
AlRifai Adriece
Publication year - 2011
Publication title -
journal of renal care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.381
H-Index - 27
eISSN - 1755-6686
pISSN - 1755-6678
DOI - 10.1111/j.1755-6686.2011.00230.x
Subject(s) - paricalcitol , medicine , secondary hyperparathyroidism , parathyroid hormone , kidney disease , hyperparathyroidism , endocrinology , vitamin d and neurology , renal function , proteinuria , calcitriol receptor , urology , kidney , calcium
SUMMARY Secondary hyperparathyroidism is a characteristic feature of chronic kidney disease, which develops early in the course of chronic kidney disease, often in a progressive way. It occurs as the renal function continues to decline and is encountered following a series of biochemical abnormalities, which are responsible for initiation and maintenance of increased parathyroid hormone (PTH) secretion. Several agents are used in the management of secondary hyperparathyroidism. Paricalcitol is a new generation selective vitamin D receptor activator that lowers PTH levels by exerting a less hypercalcaemic and hyperphosphataemic effect. In addition, there is emerging evidence of the benefit of paricalcitol in preventing intravascular calcification and proteinuria.